Belgium-based immunotherapy developer iTeos Therapeutics, spun out from Université catholique de Louvain (UCL) and Ludwig Institute for Cancer Research, raised €64m ($74m) in series B funding yesterday.

The oversubscribed round featured university venture fund Vives Louvain Technology Fund, managed by UCL’s tech transfer office Sopartec, and was led by private equity firm MPM Capital.

6 Dimensions Capital, an investment firm formed by pharmaceutical firm WuXi AppTec and VC firm Frontline BioVentures, also contributed to the round, as did Walloon government-backed…